NCT05417750 (MIZAR-001) is a Phase 1 clinical trial of TIL therapy in Tumor Infiltrating Lymphocytes, sponsored by Shanghai Juncell Therapeutics.

Who is sponsoring NCT05417750?

NCT05417750 is sponsored by Shanghai Juncell Therapeutics.

What drugs are being tested in NCT05417750?

Interventions in NCT05417750: TIL therapy.

What condition does NCT05417750 study?

NCT05417750 studies Tumor Infiltrating Lymphocytes, Safety, Advanced Solid Tumor, Immunotherapy, Efficacy, Adverse Drug Event.

Is NCT05417750 still recruiting?

NCT05417750 is currently completed. Last updated 10 December 2025.

Last reviewed 2025-12-10 · How we verify

NCT05417750: MIZAR-001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study of GC101 TIL in Advanced Solid Tumors

Completed Phase 1 Last updated 10 December 2025

What this trial tests

Phase 1 trial testing TIL therapy in Tumor Infiltrating Lymphocytes in 43 participants. Completed in 30 October 2025.

Timeline

12 October 2022

Primary endpoint
30 April 2025

30 October 2025

Quick facts

Lead sponsor	Shanghai Juncell Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	43
Start date	12 October 2022
Primary completion	30 April 2025
Estimated completion	30 October 2025
Sites	1 location across China

Drugs / interventions tested

TIL therapy — full drug profile →

Conditions studied

Tumor Infiltrating Lymphocytes — all drugs for Tumor Infiltrating Lymphocytes →
Safety — all drugs for Safety →
Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
Immunotherapy — all drugs for Immunotherapy →

Sponsor

Shanghai Juncell Therapeutics — full company profile →

Who can join

Adults 18 to 75, any sex, with Tumor Infiltrating Lymphocytes or Safety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

20-60 participants are expected to be enrolled for the Phase I clinical trial which is further divided into two parts: a "3+3" dose escalation study and an expanded enrollment study. The Phase I clinical trial is expected to be finished in 36 months. To be specific, the dose escalation study plans to include patients with advanced malignant solid tumors with clear pathological diagnosis, including melanoma, cervical cancer, head and neck squamous cell tumors, non-small cell lung cancer and breast cancer, etc.; while the expanded enrollment study plans to include those with melanoma, cervical cancer, and head and neck squamous cell tumors.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Recent clinical researches and technological development in TIL therapy.
Matsueda S, Chen L, Li H, Yao H, et al · · 2024 · cited 23× · PMID 39264449 · DOI 10.1007/s00262-024-03793-4
IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer.
Guo J, Wang C, Luo N, Wu Y, et al · · 2024 · cited 7× · PMID 38769543 · DOI 10.1186/s12916-024-03420-0
Advances in Adoptive Cell Therapies in Cancer: From Mechanistic Breakthroughs to Clinical Frontiers and Overcoming Barriers.
Rabbani SA, El-Tanani M, El-Tanani Y, Kumar R, et al · · 2025 · cited 1× · PMID 40981188 · DOI 10.3390/medsci13030190
Tumor-infiltrating lymphocytes and tumor-associated macrophages in cancer immunoediting: a targetable therapeutic axis.
Mukherjee S, Ghosh A, Chakraborty S, Basak U, et al · · 2025 · PMID 41019045 · DOI 10.3389/fimmu.2025.1655176

Verify or expand the search:

Other trials of TIL therapy

Trials testing the same drug.

NCT06783270 — T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma · Phase 1 · recruiting

Other recruiting trials for Tumor Infiltrating Lymphocytes

Currently open trials in the same condition.

NCT06828328 — A Study of GC203 TIL in PDCA (RJ) · EARLY_PHASE1 · recruiting
NCT06488950 — A Study of TIL in Advanced Solid Tumors (DFGD) · EARLY_PHASE1 · recruiting
NCT05087745 — A Clinical Study on TIL for the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting

Other Shanghai Juncell Therapeutics trials

Trials by the same sponsor.

NCT07294872 — A Study of TIL in Advanced Solid Tumors (CZ) · Phase 1 · not yet recruiting
NCT07256756 — A Study of GC203 TIL in Advanced Solid Tumors (NF) · Phase 1 · not yet recruiting
NCT06828328 — A Study of GC203 TIL in PDCA (RJ) · EARLY_PHASE1 · recruiting
NCT06703398 — A Study of GC101 TIL in Advanced Melanoma · Phase 2 · recruiting
NCT06473961 — A Phase Ib Study of GC101 in NSCLC · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05417750 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Juncell Therapeutics
Last refreshed: 10 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05417750.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing